TY - JOUR
AU1 - Goyal, Mayank
AU2 - Orlov, Kirill
AU3 - Jensen, Mary E.
AU4 - Taylor, Allan
AU5 - Majoie, Charles
AU6 - Jayaraman, Mahesh
AU7 - Liu, Jianmin
AU8 - Milot, Geneviève
AU9 - Brouwer, Patrick
AU1 - Yoshimura, Shinichi
AU1 - Albuquerque, Felipe
AU1 - Arthur, Adam
AU1 - Kallmes, David
AU1 - Sakai, Nobuyuki
AU1 - Fraser, Justin F.
AU1 - Nogueira, Raul
AU1 - Yang, Pengfei
AU1 - Dorn, Franziska
AU1 - Thibault, Lucie
AU2 - Fiehler, Jens
AU2 - Chapot, René
AU2 - Ospel, Johanna Maria
AB - PurposeThere is little data and lack of consensus regarding antiplatelet management for intracranial stenting due to underlying intracranial atherosclerosis in the setting of endovascular treatment (EVT). In this DELPHI study, we aimed to assess whether consensus on antiplatelet management in this situation among experienced experts can be achieved, and what this consensus would be.MethodsWe used a modified DELPHI approach to address unanswered questions in antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of EVT. An expert-panel (19 neurointerventionalists from 8 countries) answered structured, anonymized on-line questionnaires with iterative feedback-loops. Panel-consensus was defined as agreement ≥ 70% for binary closed-ended questions/≥ 50% for closed-ended questions with > 2 response options.ResultsPanel members answered a total of 5 survey rounds. They acknowledged that there is insufficient data for evidence-based recommendations in many aspects of antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of EVT. They believed that antiplatelet management should follow a standardized regimen, irrespective of imaging findings and reperfusion quality. There was no consensus on the timing of antiplatelet-therapy initiation. Aspirin was the preferred antiplatelet agent for the peri-procedural period, and oral Aspirin in combination with a P2Y12 inhibitor was the favored postprocedural regimen.ConclusionData on antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of EVT are limited. Panel-members in this study achieved consensus on postprocedural antiplatelet management but did not agree upon a preprocedural and intraprocedural antiplatelet regimen. Further prospective studies to optimize antiplatelet regimens are needed.
TI - A DELPHI consensus statement on antiplatelet management for intracranial stenting due to underlying atherosclerosis in the setting of mechanical thrombectomy
JF - Neuroradiology
DO - 10.1007/s00234-020-02556-z
DA - 2020-09-24
UR - https://www.deepdyve.com/lp/springer-journals/a-delphi-consensus-statement-on-antiplatelet-management-for-oIrNTQKEEv
SP - 627
EP - 632
VL - 63
IS - 4
DP - DeepDyve
ER -